AEs). Pooled hazard ratio (HR) for survival outcomes (PFS and OS) and pooled risk ratio (RR) for dichotomous data (ORR and AEs) with 95% CI were calculated. Result: 17 RCTs with 6,616 patients were included in this meta-analysis. The combination therapy of ICI was significantly associated with improvement of ORR (RR ¼ 1.56 [95% CI 1.24, 1.96], P ¼ 0.0001), PFS (HR ¼ 0.69 [95% CI 0.59, 0.81], P < 0.00001) and OS (HR ¼ 0.76 [95% CI 0.67, 0.87], P < 0.0001) in solid tumor. In subgroup analyses, combination ICI therapy obviously prolonged OS in melanoma patients (HR ¼ 0.64 [95% CI 0.57, 0.72], p<0.00001), but not in SCLC (HR ¼ 0.94 [95% CI 0.82, 1.08], P ¼ 0.40) and NSCLC (HR ¼ 0.92 [95% CI 0.79, 1.07], P ¼ 0.26) patients. As for toxicity, there was an increased risk of fatigue, rash, diarrhoea and increased transaminases with combination ICI therapy. Conclusion: In conclusion, our meta-analysis found that combination ICI therapy showed significant benefits in ORR, PFS and OS for patients with solid tumors. Both of combination of ICI with chemoradiotherapy and dual ICI were effective and relatively safe. Melanoma patients got definite survival benefit from combination ICI therapy. There was also a tendency of improvement of survival for SCLC and NSCLC patients.
P3.04-19 Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis J. Raphael, 1 A. Batra, 1 G. Boldt, 1 P. Shah, 2 P. Blanchette, 1 G. Rodrigues, 1 M. Vincent 1 1 Department of Oncology, London Regional Cancer Program -Western University, London, ON/CA, 2 Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON/CA Background: Checkpoint inhibitors targeting the programmed death-1 (PD-1)/PD-ligand 1 (L1) pathway have become a standard treatment in advanced non-small cell lung cancer (NSCLC) in the first and second line setting. Yet, subgroup analyses from randomized trials have shown inconsistent results regarding survival benefit in elderly patients (> 65 years old), never-smokers and patients with PD-L1 (-) expressing tumors (<1%). We conducted a systematic review and meta-analysis to assess the efficacy of checkpoint inhibitors in these pre-defined subgroups of patients. Method: The electronic databases PubMed and EMBASE, were searched for relevant randomized trials between January 2005 and December 2017. Pooled hazard ratios (HR) for overall survival (OS) and progression free survival (PFS) were metaanalyzed using the generic inverse variance method. To account for between-studies heterogeneity, random-effect models were used to compute pooled estimates. Subgroup analyses compared patients treated in the first versus second line setting. Result: Seven studies were included. Compared to chemotherapy, a significant reduction in the risk of death was seen with the use of checkpoint inhibitors in the second line independent of PD-L1 expression (4 studies, 2,364 participants, HR¼0.79, 95%CI 0.66-0.96 and HR¼0.66, 95%CI 0.57-0.78 in PD-L1 (e) and (+) patients respectively). Yet, a PFS benefit was only seen in patients with PD-L1 (+) tumors (2 studies, 852 participants, HR¼0.69, 95%CI 0.55-0.88). Similarly, an OS benefit was seen in patients independent of age (5 studies, 3,651 participants, HR¼0.77, 95% CI 0.64-0.92 and HR¼0.75, 95%CI 0.6-0.94 in elderly and non-elderly patients respectively). Conversely, an OS benefit was only seen in eversmokers (5 studies, 2,905 participants, HR¼0.76, 95%CI 0.63-0.92 in ever-smokers and HR¼0.83, 95%CI 0.64-1.08 in never-smokers) and a detrimental effect on PFS in never-smokers (3 studies, 1,426 participants, HR¼1.68, 95%CI 1.07-2.63). In subgroup analyses, with the use of checkpoint inhibitors, elderly patients derived an OS benefit only in the second line setting (HR¼0.69, 95%CI 0.59-0.81). Furthermore, never-smokers had no OS benefit in the first or second line (HR¼1.02, 95%CI 0.54-1.93 and HR¼0.79, 95%CI 0.59-1.07 respectively) and worse PFS particularly in the first line (HR¼2.3, 95%CI 1.23-4.3). Conclusion: In the second line setting, patients with advanced NSCLC derive a survival benefit from checkpoint inhibitors independent of tumor PD-L1 expression and age. However, never-smokers do not benefit from these drugs particularly in the first line. Caution should be exercised when offering checkpoint inhibitors to elderly patients with advanced NSCLC in the first line and further research is needed to define their role in never-smokers. Background: Immune checkpoint inhibitors (ICIs) are associated with a unique set of toxicities termed immune-related adverse events (irAEs). The association between response to ICI therapy and development of irAEs has been documented in various cancer types. Method: Stage IV non-small cell lung cancer (NSCLC) patients treated with ICIs at the Princess Margaret Cancer Centre between 2013 and 2016 were followed for treatment response, treatment duration, survival, and toxicity. The relationship between treatment outcomes and occurrence of irAEs was examined. Result: A total of 97 advanced NSCLC patients were followed. Most patients (81%) received anti-PD-1 agents, 17% received anti-PD-L1 agents, and 2% received combination anti-PD-L1 plus anti-CTLA-4 therapy. Median follow up for the cohort was 5.1 months (0.3-38.1 months) from treatment start. Demographic and tumour characteristics were balanced between the groups. IrAEs occurred in half of patients (51%) on ICIs and grade3 irAEs in 7%. The most commonly observed irAEs were arthralgia (13%), diarrhea/colitis (12%), and skin rash (11%). Discontinuation of treatment due to irAEs occurred in 10% of patients, half of whom experienced grade3 irAEs. The overall response rate to ICIs was 23%, with the majority occurring by week 8 of treatment (16/22). Response was non-evaluable in one patient and this was excluded from response analysis. Patients with grade3 irAEs were more likely to have response to treatment compared to those with grade I/II irAEs and no irAEs (67% vs 17% vs 23%, p¼0.035), Table 1 . Smoking status was not associated with response rate or frequency of irAEs. Median survival was not reached in those with grade3 irAEs, 15.7 months in those with grade I/II irAEs, and 7.4 months in those with no irAE (p¼0.16). Duration of treatment did not differ significantly among the groups. Conclusion: The occurrence of grade3 irAEs may be associated with treatment response in advanced NSCLC patients undergoing ICI therapy. Keywords: immune related Adverse event, immune checkpoint inhibitor, lung cancer
October 2018
Abstracts S929
